# Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

> **NCT05861128** · PHASE3 · UNKNOWN · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 258 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Jaktinib

## Key facts

- **NCT ID:** NCT05861128
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861128, "Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05861128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*